PARP inhibitors

Research Reports

Treatment Duration, Adherence, Interruptions, and Discontinuations Associated With Maintenance Regimens for Recurrent Ovarian Cancer

06/05/2023

Emma L. Barber, MD

Allison M. Saiz, MD

Nicole M. Engel-Nitz, PhD

Scott H. Bunner, MPH

Katrine L. Wallace, PhD

Emma L. Barber, MD, and colleagues investigate current and real-world practice patterns for patients receiving maintenance therapy for recurrent ovarian cancer after second-line chemotherapy.

Emma L. Barber, MD, and...

06/05/2023

Journal of Clinical Pathways

News

Cost-Sharing Patterns for PARP Inhibitor Therapy in Ovarian Cancer

02/12/2021

Journal of Clinical Pathways

News

Total and Out-of-Pocket Costs of PARP Inhibitor Therapy for Ovarian Cancer

01/21/2021

Journal of Clinical Pathways

Special Report

Overview of the Updated NCCN Guidelines on Ovarian Cancer

06/17/2020

While ovarian cancer is the second most common gynecologic cancer in the United States, behind uterine cancer,1 it is the top gynecologic cancer in mortality.2 In 2020, an estimated 21,750 new cases of ovarian cancer...

While...

06/17/2020

Journal of Clinical Pathways

News

PARP Inhibitor vs Nonplatinum Chemo for Platinum-Sensitive, Relapsed Ovarian Cancer

06/09/2020

Olaparib improves survival outcomes for patients with germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer who received at least two prior lines of platinum-based chemotherapy, according to a...

...

06/09/2020

Journal of Clinical Pathways

ENGAGING EXPERTS

Ovarian Cancer Maintenance: PRIMA, PAOLA-1, VELIA, and Others

06/05/2020

Michael Birrer, MD, PhD, director of the Winthrop P Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, discusses the latest PARP inhibitor indications for frontline maintenance in ovarian cancer, as well as the...

Michael Birrer, MD, PhD,...

06/05/2020

Journal of Clinical Pathways

News

Utility of Genomic Instability Test Scores for Predicting PARP Response in Ovarian Cancer

06/03/2020

HRD test results used in published and ongoing clinical trials for PARP inhibitor-treatment of ovarian cancer are not equivalent, according to the results of a study presented at the American Society of Clinical...

HRD...

06/03/2020

Journal of Clinical Pathways